Request Demo
Last update 06 Dec 2025
Bevacizumab Biosimilar (BioXpress Therapeutics)
Last update 06 Dec 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (BioXpress Therapeutics SA), BXT 2316, BXT-2316 + [1] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Structure/Sequence
Sequence Code 41632H
The sequence is quoted from: *****
Sequence Code 41637L
The sequence is quoted from: *****
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | Switzerland | 13 Mar 2024 | |
| Fallopian Tube Carcinoma | Preclinical | Switzerland | 13 Mar 2024 | |
| Glioblastoma Multiforme | Preclinical | Switzerland | 13 Mar 2024 | |
| Non-Small Cell Lung Cancer | Preclinical | Switzerland | 13 Mar 2024 | |
| Ovarian Cancer | Preclinical | Switzerland | 13 Mar 2024 | |
| Peritoneal Neoplasms | Preclinical | Switzerland | 13 Mar 2024 | |
| Renal Cell Carcinoma | Preclinical | Switzerland | 13 Mar 2024 | |
| Uterine Cervical Cancer | Preclinical | Switzerland | 13 Mar 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free